Incyte said Hervé Hoppenot retired as President and Chief Executive Officer effective June 26, 2025 and will remain on the Board of Directors. Julian C. Baker assumed the role of Chairman of the Board on the same day.

1. 01

   Incyte said Hervé Hoppenot retired as President and Chief Executive Officer effective June 26, 2025 and will remain on the Board of Directors. Julian C. Baker assumed the role of Chairman of the Board on the same day.

2. 02

   The company said it appointed William J. Meury as President and Chief Executive Officer effective June 26, 2025 and also appointed him to the Board. The filing says he previously served as President and Chief Executive Officer of Karuna Therapeutics and Anthos Therapeutics.

3. 03

   Incyte said Meury will receive an initial annual base salary of $1,250,000, a cash bonus target of 100% of base salary under the Incentive Compensation Plan pro-rated for 2025. The company also granted regular annual equity awards of 36,101 RSUs, 110,630 options and a target of 108,303 performance shares.

4. 04

   Incyte said its Transition Agreement with Hoppenot provides for compensation at an annual base salary of $1,395,731 for the first 6 months, and at 50% of that rate for the following 6 months. The company also increased the number of shares authorized under its 2024 Inducement Stock Incentive Plan from 1,000,000 to 2,000,000 shares.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.